![Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/asset/6274b34d-6af7-410f-8989-51c40dac5a35/gr2.jpg)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
![A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients | medRxiv A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/12/17/2021.12.16.21267932/F6.large.jpg)
A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients | medRxiv
![Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-27674-x/MediaObjects/41467_2021_27674_Fig3_HTML.png)
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
![Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer? - Forgham - 2022 - Exploration - Wiley Online Library Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer? - Forgham - 2022 - Exploration - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/eae933b4-d8ab-4c61-b9b8-4570c35cb18f/exp2118-fig-0001-m.jpg)
Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer? - Forgham - 2022 - Exploration - Wiley Online Library
![Frontiers | Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants Frontiers | Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants](https://www.frontiersin.org/files/MyHome%20Article%20Library/836826/836826_Thumb_400.jpg)
Frontiers | Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
![Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy](https://www.cell.com/cms/attachment/e0a5c5da-c9bc-480f-a819-01e299f2dfab/gr7_lrg.jpg)
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy
Lena Batoon on LinkedIn: Congratulations on this recent publication, Sema Hakki! Thanks for letting…
![Frontiers | Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants Frontiers | Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants](https://www.frontiersin.org/files/MyHome%20Article%20Library/804945/804945_Thumb_400.jpg)
Frontiers | Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
![Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China - Tian - 2022 - Journal of Medical Virology - Wiley Online Library Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China - Tian - 2022 - Journal of Medical Virology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d36fdfb7-caea-43f5-994f-5b63611057ef/jmv.v94.5.cover.jpg?trick=1703585522094)
Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China - Tian - 2022 - Journal of Medical Virology - Wiley Online Library
![IJMS | Free Full-Text | Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review IJMS | Free Full-Text | Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review](https://pub.mdpi-res.com/ijms/ijms-23-01987/article_deploy/html/images/ijms-23-01987-g001-550.jpg?1644572917)
IJMS | Free Full-Text | Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review
![Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 - ScienceDirect Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S009286742200527X-gr4.jpg)
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 - ScienceDirect
![Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination | Journal of Virology Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination | Journal of Virology](https://journals.asm.org/cms/10.1128/jvi.01664-22/asset/383bbf97-8bfc-40fa-bbdc-c547e52f76fe/assets/images/large/jvi.01664-22-f003.jpg)
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination | Journal of Virology
![Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data | BMC Infectious Diseases | Full Text Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data | BMC Infectious Diseases | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12879-022-07777-6/MediaObjects/12879_2022_7777_Fig4_HTML.png)
Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data | BMC Infectious Diseases | Full Text
![Frontiers | Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127 Frontiers | Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127](https://www.frontiersin.org/files/Articles/978052/fpubh-10-978052-HTML/image_m/fpubh-10-978052-g001.jpg)
Frontiers | Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
![Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-27674-x/MediaObjects/41467_2021_27674_Fig1_HTML.png)
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
![Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy](https://www.cell.com/cms/attachment/d649e9f8-897e-4a30-83c3-4b00fd3f3d25/gr5_lrg.jpg)
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy
![Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-27674-x/MediaObjects/41467_2021_27674_Fig2_HTML.png)
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
![Frontiers | Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic Frontiers | Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic](https://www.frontiersin.org/files/Articles/1130398/fimmu-14-1130398-HTML/image_m/fimmu-14-1130398-g001.jpg)